Cognito Therapeutics, a Phase 3-ready disease-modifying digital therapeutics company, today announced the appointment of Gerald Chan, ScD. as Chairman of the Board. Cognito is a pioneer in using neuromodulation to engage novel targets of neuronal pathophysiology to achieve disease modification in neurodegenerative diseases. Dr. Chan is the co-founder of Morningside, a privately held venture capital and private equity firm. Since inception, Morningside has focused on the development and commercialization of novel scientific discoveries in both the life sciences and technology sectors. "The use of non-pharmacological interventions to treat neurocognitive decline represents a fundamental shif

Maxim Group initiated coverage of Stealth BioTherapeutics with a rating of Buy and set a new price target of $3.00

BOSTON, Nov. 16, 2022 /PRNewswire/ -- Stealth BioTherapeutics Corp (NASDAQ:MITO) (the "Company" or "Stealth BioTherapeutics"), a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies for diseases involving mitochondrial dysfunction, announced today the completion of the merger (the "Merger") with Stealth Merger Sub Limited, an exempted company with limited liability incorporated under the law of the Cayman Islands ("Merger Sub"), pursuant to the previously announced Agreement and Plan of Merger, dated as of July 31, 2022 (the "Merger Agreement"), among the Company, Stealth Parent Limited, an exempted company with limited liabilit

SBT-272 Phase 1 safety and tolerability data support further clinical development SBT-272 was neuroprotective and reduced neuroinflammation in ALS preclinical model SBT-272 Granted Orphan Drug Designation for Treatment of ALS BOSTON, Nov. 1, 2022 /PRNewswire/ -- Stealth BioTherapeutics Corp (NASDAQ:MITO), a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced encouraging Phase 1 data on the safety and tolerability of SBT-272, a next-generation small molecule designed to reach therapeutic concentrations in the brain and to restore mitochondrial structure and functi

BOSTON, Oct. 7, 2022 /PRNewswire/ -- Stealth BioTherapeutics Corp (NASDAQ:MITO) ("Stealth" or the "Company"), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, announced today that it has called an extraordinary general meeting of shareholders (the  "EGM"), to be held at 9:30 a.m. (New York City time) on November 15, 2022, at Foley & Lardner LLP, 111 Huntington Ave Suite 2600, Boston, MA 02199, to consider and vote on, among other matters, the proposal to authorize and approve the previously announced agreement and plan of merger, dated as of July 31, 2022 (the "Merger Agreem

BOSTON, Sept. 30, 2022 /PRNewswire/ -- Stealth BioTherapeutics Corp (NASDAQ:MITO), a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced that Robert Weiskopf, Stealth's chief financial officer, is leaving the company effective September 30, 2022. Mr. Weiskopf joined Stealth in 2019 following the company's initial public offering to spearhead its public financial reporting activities and grow the Company's financial team. "On behalf of the entire te

BOSTON, Sept. 15, 2022 /PRNewswire/ -- Stealth BioTherapeutics Corp (NASDAQ:MITO), a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced that the company is participating in upcoming events to discuss challenges and opportunities in ultra-rare disease drug development. Reenie McCarthy, Stealth's CEO, will be participating in "Rare Disease Research: A Prescription" hosted by STAT which will take place on Thursday, September 15th from 5:30 p.m.–9:00

BOSTON, Aug. 1, 2022 /PRNewswire/ -- Stealth BioTherapeutics Corp (NASDAQ:MITO), a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies for diseases involving mitochondrial dysfunction, announced today that it has entered into a definitive Agreement and Plan of Merger (the "Merger Agreement") with Stealth Parent Limited, an exempted company with limited liability incorporated under the law of the Cayman Islands ("Parent"), and Stealth Merger Sub Limited, an exempted company with limited liability incorporated under the law of the Cayman Islands and a wholly-owned subsidiary of Parent ("Merger Sub"), to be acquired by a consortiu

BOSTON, July 11, 2022 /PRNewswire/ -- Stealth BioTherapeutics Corp (NASDAQ:MITO), a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies for diseases involving mitochondrial dysfunction, announced that it received a letter from the Listing Qualifications department of The Nasdaq Stock Market LLC ("Nasdaq") on July 7, 2022 notifying the Company that, based upon the Company's continued non-compliance with the minimum bid price and market value of listed securities requirements, as set forth in Nasdaq Listing Rules 5450(a)(1) and 5450(b)(2), the Company's securities would be delisted from Nasdaq unless the Company timely requests a

BOSTON, June 27, 2022 /PRNewswire/ -- Stealth BioTherapeutics Corp (NASDAQ:MITO), a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies for diseases involving mitochondrial dysfunction, announced today that its Board of Directors (the "Board") has received a preliminary non-binding proposal letter dated June 24, 2022 (the "Proposal Letter") from Morningside Venture (I) Investments Ltd. for itself and on behalf of its affiliates ("Morningside") and J. Wood Capital Advisors LLC ("J. Wood Capital") to acquire all outstanding ordinary shares (the "Shares") of the Company not already beneficially owned by Morningside, including Shar

Type B meeting scheduled with FDA Division of Cardiology and Nephrology Company plans to discuss new clinical data that may inform a potential NDA submission BOSTON, June 14, 2022 /PRNewswire/ -- Stealth BioTherapeutics Corp (NASDAQ:MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced its plan to meet with the U.S. Food & Drug Administration (FDA) Division of Cardiology and Nephrology (DCN) to discuss new clinical data that may inform a potential new drug application (NDA) submission for the treatment of Barth Syndrome.

SBT-272 improved neuronal health, superior to other approved and investigational agents Phase 1 study to evaluate safety and tolerability of SBT-272 in healthy volunteers is underway BOSTON, June 8, 2022 /PRNewswire/ -- Stealth BioTherapeutics Corp (NASDAQ:MITO), a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies for diseases involving mitochondrial dysfunction, announced today the presentation of new SBT-272 preclinical data demonstrating functional improvement in upper motor neurons with TDP-43 pathology, which plays a significant role in both amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). The data

SC 13D/A - Stealth BioTherapeutics Corp (0001696396) (Subject)

SC 13D/A - Stealth BioTherapeutics Corp (0001696396) (Subject)

SC 13D/A - Stealth BioTherapeutics Corp (0001696396) (Subject)

SC 13D/A - Stealth BioTherapeutics Corp (0001696396) (Subject)

SC 13D/A - Stealth BioTherapeutics Corp (0001696396) (Subject)

SC 13D/A - Stealth BioTherapeutics Corp (0001696396) (Subject)

SBT-272 Phase 1 safety and tolerability data support further clinical development SBT-272 was neuroprotective and reduced neuroinflammation in ALS preclinical model SBT-272 Granted Orphan Drug Designation for Treatment of ALS BOSTON, Nov. 1, 2022 /PRNewswire/ -- Stealth BioTherapeutics Corp (NASDAQ:MITO), a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced encouraging Phase 1 data on the safety and tolerability of SBT-272, a next-generation small molecule designed to reach therapeutic concentrations in the brain and to restore mitochondrial structure and fun

On Thursday, shares of Stealth BioTherapeutics Corp (NASDAQ:MITO) experienced volatile short activity. After the activity, the stock price went up +0.35% to $0.286. The overall sentiment for MITO has been Bearish. The signal from the volatility alert is trending Bearish. Therefore, the recommendation is to Strong Sell. The volatility alert was produced on the prior trading date, 8/4/2022 with a volatility change of +78.08%. The current volatility indicator stands at 5.668. Overview: The securities lending volatility indicator is produced by Tidal Markets, in partnership with Benzinga Insights. Securities lending primarily serves the purpose of providing liquidity to short sellers. When u

Gainers Liberty TripAdvisor Holdings, Inc. (NASDAQ:LTRPB) shares jumped 187.3% to close at $48.03 on Monday after gaining around 18% on Friday. Virax Biolabs Group Limited (NASDAQ:VRAX) climbed 119.4% to settle at $11.85 on Monday after declining 74% on Friday. Ontrak, Inc. (NASDAQ:OTRK) shares jumped 107.7% to close at $1.35 on Monday. Ontrak is expected to report financial results for the second quarter on Tuesday, August 9, 2022. Revlon, Inc. (NYSE:REV) gained 89.9% to close at $8.49 following a Reuters report suggesting a US bankruptcy judge has given the company permission to proceed with a $1.4 billion loan. AMTD Digital Inc. (NYSE:HKD) rose 85.4% to settle at $742.00 on contin

Gainers Conformis (NASDAQ:CFMS) shares moved upwards by 13.2% to $0.29 during Monday's after-market session. The company's market cap stands at $53.5 million. OKYO Pharma (NASDAQ:OKYO) stock rose 13.08% to $2.68. Trading volume for this security closed at 111.8K, accounting for 101.1% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $58.3 million. Aytu BioPharma (NASDAQ:AYTU) shares rose 11.96% to $0.57. The market value of their outstanding shares is at $21.9 million. Cabaletta Bio (NASDAQ:CABA) stock moved upwards by 11.3% to $1.28. The market value of their outstanding shares is at $37.0 million. AN2 Therapeutics (NASDAQ:ANTX)

Gainers Ontrak, Inc. (NASDAQ:OTRK) gained 102% to $1.3150. Ontrak is expected to report financial results for the second quarter on Tuesday, August 9, 2022. Virax Biolabs Group Limited (NASDAQ:VRAX) jumped 83.7% to $9.92 after declining 74% on Friday. Mobile Global Esports Inc. (NASDAQ:MGAM) shares gained 56% to $17.47 on post-IPO volatility following Friday's IPO, which was priced at $4 per share. MediaCo Holding Inc. (NASDAQ:MDIA) shares climbed 55% to $3.21. MediaCo Holding 10% owner Soohyung Kim bought a total of 12,899,480 shares at an average price of $2.32. Nanobiotix S.A. (NASDAQ:NBTX) gained 43.1% to $3.32. Aethlon Medical, Inc. (NASDAQ:AEMD) rose 41% to $1.4006 after dro

Stealth BioTherapeutics Corp (NASDAQ:MITO) will be acquired by a consortium of investors led by Morningside Venture (I) Investments Ltd and J. Wood Capital Advisors LLC in an all-cash transaction.  Each Stealth Bio will be canceled and cease to exist for the right to receive $0.03125 in cash. Each American Depositary Share representing 12 shares will be canceled for the right to receive $0.375. Related: Stealth Bio Shares Trading Higher On Pre-Clinical Presentation Of Neuromuscular Disease Candidate. The merger consideration represents a premium of 34.4% to the closing price on June 24, the last trading day before the company announced its receipt of the original "going-private" proposa

Stealth BioTherapeutics Corp (NASDAQ:MITO), a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies for diseases involving mitochondrial dysfunction, announced today that it has entered into a definitive Agreement and Plan of Merger (the "Merger Agreement") with Stealth Parent Limited, an exempted company with limited liability incorporated under the law of the Cayman Islands ("Parent"), and Stealth Merger Sub Limited, an exempted company with limited liability incorporated under the law of the Cayman Islands and a wholly-owned subsidiary of Parent ("Merger Sub"), to be acquired by a consortium of investors led by Morningside Ven

BOSTON, Aug. 1, 2022 /PRNewswire/ -- Stealth BioTherapeutics Corp (NASDAQ:MITO), a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies for diseases involving mitochondrial dysfunction, announced today that it has entered into a definitive Agreement and Plan of Merger (the "Merger Agreement") with Stealth Parent Limited, an exempted company with limited liability incorporated under the law of the Cayman Islands ("Parent"), and Stealth Merger Sub Limited, an exempted company with limited liability incorporated under the law of the Cayman Islands and a wholly-owned subsidiary of Parent ("Merger Sub"), to be acquired by a consortiu

By Brad Sorensen, CFA NASDAQ:MITO READ THE FULL MITO RESEARCH REPORT Stealth BioTherapeutics (NASDAQ:MITO) is clinical stage biopharmaceutical company that is attempting to repair mitochondria to treat previously untreatable conditions. Stealth announced on June 27, 2022 the company received a no-binding proposal letter from Morningside Venture Investments to acquire all shares of the Stealth that are not already owned by Morningside for $0.313 in cash per ADS. Following are the details of the offer: • Morningside currently owns approximately 65% of Stealth. • The offer price represents an 11.7% premium to the closing price of MITO on June 24, 2022—the date of the offer letter. •